NLS Novo Nordisk

Novo Nordisk has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna) for a total equity value of approximately USD 3.3 billion. The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms […]

The companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme. PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. ATTR amyloidosis is a rare, progressive […]

The company has presented data showing that an investigational 2.0 mg dose of Ozempic provided statistically significant and superior reductions in blood sugar compared with Ozempic 1.0 mg. These data were the outcome of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing once-weekly semaglutide 2.0 mg vs Ozempic 1.0 mg […]

Heartseed Inc. and Novo Nordisk A/S have entered into an exclusive worldwide collaboration and license agreement for development, manufacturing and commercialization of Heartseed’s HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. “Through this […]

Novo Nordisk has presented results from the phase 2 randomised, double-blind, placebo controlled clinical trial assessing the effect of once-monthly, investigational ziltivekimab, an interleukin-6 (IL-6) inhibitor, on biomarkers of inflammation. The trial showed a significant reduction of multiple inflammatory biomarkers associated with atherosclerosis in people with advanced chronic kidney disease (CKD) and elevated high-sensitivity C-reactive […]

Novo Nordisk has announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg, states the company in a press release. Obesity or overweight with comorbidities Novo Nordisk intends to initiate a […]